Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 40.90%175.49M | 110.00%63.05M | 37.39%39.94M | 40.81%44.84M | -17.71%27.66M | 1,226.28%124.55M | 275.12%30.03M | 2,431.19%29.07M | 1,309.07%31.85M | 8,911.26%33.61M |
Net interest income | 26.23%164.78M | 37.78%47.26M | 23.56%42.32M | 16.62%37.95M | 26.48%37.25M | 24.70%130.54M | 12.53%34.3M | 23.00%34.25M | 31.49%32.54M | 36.29%29.45M |
-Net interest income | 29.68%226.73M | 48.20%66.31M | 31.43%59.19M | 16.41%51.84M | 21.86%49.39M | 25.93%174.84M | 9.76%44.75M | 21.21%45.04M | 36.97%44.53M | 42.68%40.53M |
-Total interest expense | 39.85%61.95M | 82.39%19.05M | 56.43%16.87M | 15.85%13.89M | 9.59%12.14M | 29.72%44.3M | 1.58%10.45M | 15.87%10.78M | 54.43%11.99M | 63.00%11.08M |
Non interest income | 278.76%10.71M | 469.58%15.8M | 53.98%-2.39M | 1,085.55%6.89M | -330.37%-9.59M | 93.71%-5.99M | 80.99%-4.27M | 82.19%-5.18M | 96.89%-699K | 119.60%4.16M |
-Fees and commissions | 56.27%10.96M | 46.39%4.52M | 83.54%2.58M | 84.96%2.8M | 5.36%1.06M | 5.27%7.02M | 315.75%3.09M | -8.60%1.4M | 60.08%1.52M | -70.72%1.01M |
Credit losses provision | ||||||||||
Non interest expense | ||||||||||
Selling and administrative expenses | 18.08%14.18M | 42.98%4.58M | 19.99%3.52M | 15.88%3.43M | -9.03%2.65M | 17.83%12.01M | 20.95%3.2M | 5.39%2.93M | 20.87%2.96M | 26.12%2.91M |
-General and administrative expense | 18.08%14.18M | 42.98%4.58M | 19.99%3.52M | 15.88%3.43M | -9.03%2.65M | 17.83%12.01M | 20.95%3.2M | 5.39%2.93M | 20.87%2.96M | 26.12%2.91M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | 48.86%118.27M | 153.64%46.64M | 43.41%25.02M | 53.24%31.47M | -34.38%15.15M | 383.90%79.45M | 1,649.12%18.39M | 253.80%17.45M | 390.62%20.54M | 375.09%23.08M |
Income tax | 4.61%2.68M | 14.18%781K | -0.96%619K | -2.14%639K | 7.04%639K | 7.16%2.56M | 70.15%684K | -4.87%625K | -0.61%653K | -11.42%597K |
Earnings from equity interest net of tax | ||||||||||
Net income | 50.33%115.6M | 159.03%45.86M | 45.06%24.4M | 55.05%30.83M | -35.48%14.51M | 353.15%76.89M | 1,214.16%17.7M | 240.18%16.82M | 357.44%19.88M | 348.05%22.49M |
Net Income continuous operations | 50.33%115.6M | 159.03%45.86M | 45.06%24.4M | 55.05%30.83M | -35.48%14.51M | 353.15%76.89M | 1,214.16%17.7M | 240.18%16.82M | 357.44%19.88M | 348.05%22.49M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 50.33%115.6M | 159.03%45.86M | 45.06%24.4M | 55.05%30.83M | -35.48%14.51M | 353.15%76.89M | 1,214.16%17.7M | 240.18%16.82M | 357.44%19.88M | 348.05%22.49M |
Preferred stock dividends | ||||||||||
Other preferred stock dividend | ||||||||||
Net income attributable to common stockholders | 50.33%115.6M | 159.03%45.86M | 45.06%24.4M | 55.05%30.83M | -35.48%14.51M | 353.15%76.89M | 1,214.16%17.7M | 240.18%16.82M | 357.44%19.88M | 348.05%22.49M |
Basic earnings per share | 10.61%2.19 | 92.50%0.77 | 7.14%0.45 | 10.91%0.61 | -51.56%0.31 | 306.25%1.98 | 900.00%0.4 | 216.67%0.42 | 320.00%0.55 | 293.94%0.64 |
Diluted earnings per share | 11.11%2.1 | 89.74%0.74 | 7.50%0.43 | 13.46%0.59 | -50.00%0.3 | 296.88%1.89 | 880.00%0.39 | 211.11%0.4 | 308.00%0.52 | 281.82%0.6 |
Dividend per share | 0.00%2.04 | 2.00%0.51 | -5.56%0.51 | -3.77%0.51 | 8.51%0.51 | 8.51%2.04 | -18.03%0.5 | 20.00%0.54 | 26.19%0.53 | 17.50%0.47 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |